<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03777631</url>
  </required_header>
  <id_info>
    <org_study_id>LIX-DS-16018</org_study_id>
    <nct_id>NCT03777631</nct_id>
  </id_info>
  <brief_title>STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study</brief_title>
  <acronym>STABLED</acronym>
  <official_title>STroke Secondary Prevention With Catheter ABLation and EDoxaban for Patients With Non-valvular Atrial Fibrillation: STABLED Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nippon Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Daiichi Sankyo Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Nippon Medical School</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation (CA) has been reported to reduce risk of stroke in patients with&#xD;
      nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA&#xD;
      has not been well elucidated in NVAF with recent cerebral infarction in prospective&#xD;
      randomized trials.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral&#xD;
      infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the&#xD;
      reported annual recurrence rate in NVAF and previous stroke patients in the &quot;real-world&quot; is&#xD;
      not low even with appropriate antithrombotic treatment; 8.6% in patients with &quot;guideline&#xD;
      adherent&quot; antithrombotic therapy and around 5% in patients treated with anticoagulant&#xD;
      therapy. NVAF and recent stroke is high-risk population for stroke recurrence even with&#xD;
      anticoagulant therapy, and developing optimal secondary prevention strategy is an urgent&#xD;
      task.&#xD;
&#xD;
      Catheter ablation (CA) is now widely used to treat symptoms related to NVAF. Some&#xD;
      retrospective studies showed a beneficial effect of CA for stroke prevention using&#xD;
      age-/sex-matching or propensity-score matching. Moreover, CA have a potential to improve&#xD;
      survival or prevent heart failure development in patients with AF. However, the effect of CA&#xD;
      for secondary stroke prevention or impact of CA for NVAF patients with recent ischemic stroke&#xD;
      for survival or developing heart failure has not been evaluated in a prospective randomized&#xD;
      trial. Therefore, in the present study, we intend to compare two groups of patients with NVAF&#xD;
      with a history of cerebral infarction: a group receiving standard medical therapy (control&#xD;
      group) and a group receiving standard medical therapy plus CA (CA group).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The included patients were randomly allocated to two groups: (1) Standard medical treatment group and (2) Catheter ablation additional group.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of cerebral infarction</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Recurrence of cerebral infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic embolism</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Symptomatic systemic embolism to other regions than brain, e.g. peripheral or visceral arteries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause death</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>All-cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Cardiovascular death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization for heart failure</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Hospitalization for heart failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any bleeding</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Any bleeding</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracranial hemorrhage</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Intracranial hemorrhage</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite events</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>all-cause death, onset of stroke, systemic embolism, hospitalization for heart failure, and serious adverse event caused by CA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of and related factors to discontinuation of Edoxaban</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>The rate of and related factors to discontinuation of Edoxaban</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of treatment-emergent adverse events (safety and tolerability)</measure>
    <time_frame>Within 1 month after CA</time_frame>
    <description>Incidence of treatment-emergent adverse events (safety and tolerability)</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of all adverse events, not restricted to CA maneuver-related adverse events</measure>
    <time_frame>Within 1 month after CA</time_frame>
    <description>Incidence of all adverse events, not restricted to CA maneuver-related adverse events</description>
  </other_outcome>
  <other_outcome>
    <measure>Drug reaction to edoxaban</measure>
    <time_frame>Up to 5 years</time_frame>
    <description>Drug reaction to edoxaban</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Atrial Fibrillation Non-Rheumatic</condition>
  <arm_group>
    <arm_group_label>Standard medical therapy group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter ablation group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed &gt;100 CA annually were participated in the present study in principle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.</description>
    <arm_group_label>Catheter ablation group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥20 or &lt;80 years at time of giving informed consent&#xD;
&#xD;
          -  Nonvalvular atrial fibrillation&#xD;
&#xD;
          -  History of stroke in previous 6 months&#xD;
&#xD;
          -  Current or planned treatment with edoxaban&#xD;
&#xD;
          -  Modified Rankin scale ≤3&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic paroxysmal AF resistant to anti-arrhythmic drugs&#xD;
&#xD;
          -  Presence of left atrial thrombus and left atrial appendage on transthoracic&#xD;
             echocardiography, computed tomography or magnetic resonance imaging&#xD;
&#xD;
          -  Unable to take anticoagulation therapy for any reason, including tendency to bleed or&#xD;
             considered at high risk for bleeding from anticoagulation therapy.&#xD;
&#xD;
          -  Presence of severe renal disorder (estimated creatinine clearance &lt;30 mL/min by&#xD;
             Cockroft-Gault equation)&#xD;
&#xD;
          -  Previous CA or surgical intervention for AF&#xD;
&#xD;
          -  History of treatment with a left atrial appendage closure device&#xD;
&#xD;
          -  Left atrial diameter ≥55 mm on transthoracic echocardiography&#xD;
&#xD;
          -  Ejection fraction ≤35% on transthoracic echocardiography&#xD;
&#xD;
          -  Persistent AF for ≥10 years&#xD;
&#xD;
          -  Pregnant or possibility of pregnancy&#xD;
&#xD;
          -  Unlikely to complete the study, such as due to progressive malignant tumor&#xD;
&#xD;
          -  Participating or planning to participate in another clinical trial&#xD;
&#xD;
          -  Unwilling to participates&#xD;
&#xD;
          -  Judged as incompatible for the study by the investigators&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazumi Kimura, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Neurology, Nippon Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shoji Furukawa</last_name>
    <phone>+81-3-5804-5045</phone>
    <email>prj-stabled@eps.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kimitsu Chuo Hospital</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michihiro Hayasaka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School Chiba Hokusoh Hospital</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasushi Miyauchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kyushu Medical Center</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasushi Okada</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ogaki Municipal Hospital</name>
      <address>
        <city>Gifu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumitada Yamashita</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teine Keijinkai Hospital</name>
      <address>
        <city>Hokkaido</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minoru Ajiki</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo Brain and Heart Center</name>
      <address>
        <city>Hyōgo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiyuki Uehara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hyogo College of Medicine College Hospital</name>
      <address>
        <city>Hyōgo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masanori Asakura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kitaharima medical center</name>
      <address>
        <city>Hyōgo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirotoshi Hamaguchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University</name>
      <address>
        <city>Iwate</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasuhiro Ishibashi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odawara Cardiovascular Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kenta Kumagai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seisho Hospital</name>
      <address>
        <city>Kanagawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masataka Takeuchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kanazawa Medical Center</name>
      <address>
        <city>Kanazawa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eishun Nitta</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kumamoto Hospital</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshiro Yonehara</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tenri Hospital</name>
      <address>
        <city>Nara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toshihiko Suenaga</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manabu Sakaguchi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jichi Medical University Hospital</name>
      <address>
        <city>Tochigi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ryota Tanaka</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuo Yamashiro</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tatsuo Amano</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nippon Medical School</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazumi Kimura</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>NTT Medical Center Tokyo</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seiji Okubo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Showa University Koto Toyosu Hospital</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuki Kamiya</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo Metropolitan Tama Medical center</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masayuki Ueda</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tsuruoka Kyoritsu Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seiichi Ichikawa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tsuruoka Municipal Shonai Hospital</name>
      <address>
        <city>Yamagata</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kazuhiko Sato</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>November 3, 2018</study_first_submitted>
  <study_first_submitted_qc>December 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2018</study_first_posted>
  <last_update_submitted>December 19, 2018</last_update_submitted>
  <last_update_submitted_qc>December 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Nippon Medical School</investigator_affiliation>
    <investigator_full_name>Kazumi Kimura</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>anticoagulation treatment</keyword>
  <keyword>catheter ablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03777631
org study id: LIX-DS-16018
nct id: NCT03777631
lead sponsor: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
Catheter ablation (CA) has been reported to reduce risk of stroke in patients with
      nonvalvular atrial fibrillation (NVAF) in retrospective studies, but risk and benefit of CA
      has not been well elucidated in NVAF with recent cerebral infarction in prospective
      randomized trials.
In patients with NVAF, stroke is an independent risk factor for a subsequent cerebral
      infarction. Although anticoagulant therapy can effectively reduce thromboembolic events, the
      reported annual recurrence rate in NVAF and previous stroke patients in the "real-world" is
      not low even with appropriate antithrombotic treatment; 8.6% in patients with "guideline
      adherent" antithrombotic therapy and around 5% in patients treated with anticoagulant
      therapy. NVAF and recent stroke is high-risk population for stroke recurrence even with
      anticoagulant therapy, and developing optimal secondary prevention strategy is an urgent
      task.

      Catheter ablation (CA) is now widely used to treat symptoms related to NVAF. Some
      retrospective studies showed a beneficial effect of CA for stroke prevention using
      age-/sex-matching or propensity-score matching. Moreover, CA have a potential to improve
      survival or prevent heart failure development in patients with AF. However, the effect of CA
      for secondary stroke prevention or impact of CA for NVAF patients with recent ischemic stroke
      for survival or developing heart failure has not been evaluated in a prospective randomized
      trial. Therefore, in the present study, we intend to compare two groups of patients with NVAF
      with a history of cerebral infarction: a group receiving standard medical therapy (control
      group) and a group receiving standard medical therapy plus CA (CA group).
allocation: Randomized
intervention model: Parallel Assignment
intervention model description: The included patients were randomly allocated to two groups: (1) Standard medical treatment group and (2) Catheter ablation additional group.
primary purpose: Prevention
masking: None (Open Label)
measure: Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.
time frame: Up to 5 years
description: Composite of recurrence of cerebral infarction, systemic embolism, all-cause death, hospitalization for heart failure.
measure: Recurrence of cerebral infarction
time frame: Up to 5 years
description: Recurrence of cerebral infarction
measure: Systemic embolism
time frame: Up to 5 years
description: Symptomatic systemic embolism to other regions than brain, e.g. peripheral or visceral arteries
measure: All-cause death
time frame: Up to 5 years
description: All-cause death
measure: Cardiovascular death
time frame: Up to 5 years
description: Cardiovascular death
measure: Hospitalization for heart failure
time frame: Up to 5 years
description: Hospitalization for heart failure
measure: Any bleeding
time frame: Up to 5 years
description: Any bleeding
measure: Intracranial hemorrhage
time frame: Up to 5 years
description: Intracranial hemorrhage
measure: Composite events
time frame: Up to 5 years
description: all-cause death, onset of stroke, systemic embolism, hospitalization for heart failure, and serious adverse event caused by CA
measure: The rate of and related factors to discontinuation of Edoxaban
time frame: Up to 5 years
description: The rate of and related factors to discontinuation of Edoxaban
measure: Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban
time frame: Up to 5 years
description: Recurrence of cerebral infarction in patients with or without discontinuation of Edoxaban
measure: Incidence of treatment-emergent adverse events (safety and tolerability)
time frame: Within 1 month after CA
description: Incidence of treatment-emergent adverse events (safety and tolerability)
measure: Incidence of all adverse events, not restricted to CA maneuver-related adverse events
time frame: Within 1 month after CA
description: Incidence of all adverse events, not restricted to CA maneuver-related adverse events
measure: Drug reaction to edoxaban
time frame: Up to 5 years
description: Drug reaction to edoxaban
arm group label: Standard medical therapy group
arm group type: No Intervention
description: The preferred anticoagulant is edoxaban. Antiarrhythmic drugs are administered as needed for the patient by well-trained cardiologists.
arm group label: Catheter ablation group
arm group type: Active Comparator
description: Catheter ablation (CA) should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required. For conducting CA by a trained and experienced cardiologist, only institutions in which performed >100 CA annually were participated in the present study in principle.
intervention type: Procedure
intervention name: Catheter ablation
description: CA should be performed within 1-6 months from the onset of cerebral infarction. CA is based on pulmonary vein isolation, with atrial ablation as required.
arm group label: Catheter ablation group
criteria: 
gender: All
minimum age: 20 Years
maximum age: 79 Years
healthy volunteers: No
last name: Kazumi Kimura, M.D., Ph.D
role: Principal Investigator
affiliation: Department of Neurology, Nippon Medical School
last name: Shoji Furukawa
phone: +81-3-5804-5045
email: prj-stabled@eps.co.jp
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
facility: 
status: Recruiting
contact: 
country: Japan
responsible party type: Principal Investigator
investigator affiliation: Nippon Medical School
investigator full name: Kazumi Kimura
investigator title: Professor
mesh term: Stroke
mesh term: Ischemic Stroke
mesh term: Atrial Fibrillation
sharing ipd: Undecided